Incannex Healthcare Ltd in Australia develops and markets medicinal cannabinoid products, including IHL-42X for sleep apnea, IHL-216A for traumatic brain injury, and IHL-675A for inflammatory lung conditions, rheumatoid arthritis, and bowel diseases. The company has partnerships with Novotech and The Alfred Hospital for IHL-42X and Monash Trauma Group at Monash University for IHL-216A. The company, formerly Impression Healthcare Ltd, was created in 2001 and is headquartered in Sydney, Australia.